Bio-Rad Laboratories Stock Forecast for 2023 - 2025 - 2030
Updated on 02/05/2023
Bio-Rad Laboratories Stock Forecast and Price Target
Year-long price target forecasts from prominent analysts have recently been released for Bio-Rad Laboratories, with an average price target of $582.50. This potential gain of 23.7 percent from the previous closing price in February, 2023 is calculated on a high forecast of $640.00 and a low estimate of $550.00. If you're thinking of investing in BIO stock, it might be good to look at its rivals too.
23.70% Upside
Bio-Rad Laboratories Fair Value Forecast for 2023 - 2025 - 2030
Bio-Rad Laboratories's Price has grown in the last two years, jumping from $330.48 to $733.04 – an increase of 121.81%. The next year, 0 experts forecast that Bio-Rad Laboratories's Fair Value will decrease by 32.84%, reaching $492.29. In 2030, professionals predict that Bio-Rad Laboratories's Fair Value will decrease by 26.15%, reaching $541.38.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
11
|
$164.61 | $181.05 | 9.65% |
| ROG Stock Forecast | Roche Holding | Outperform |
5
|
CHF293.60 | CHF384.23 | 24.32% |
| AVGO Stock Forecast | Broadcom | Outperform |
9
|
$597.62 | $654.63 | 10.27% |
| TMO Stock Forecast | Thermo Fisher Scientific Inc | Outperform |
10
|
$587.76 | $618.99 | 5.49% |
| DHR Stock Forecast | Danaher Corp | Outperform |
10
|
$269.85 | $304.24 | 12.84% |
Bio-Rad Laboratories Revenue Forecast for 2023 - 2025 - 2030
Bio-Rad Laboratories's Revenue has grown in the last two years, jumping from $2.31B to $2.92B – an increase of 26.43%. The next year, 0 experts forecast that Bio-Rad Laboratories's Revenue will decrease by 11.66%, reaching $2.58B. In 2030, professionals predict that Bio-Rad Laboratories's Revenue will decrease by 10.57%, reaching $2.61B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$111.79 | $120.97 | 11.82% |
| SIE Stock Forecast | Siemens | Outperform |
6
|
145.02€ | 156.55€ | 6.88% |
| 6758 Stock Forecast | Sony Group | Buy |
3
|
¥10.64k | ¥0.00 | 41.98% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
10
|
185.90€ | 209.03€ | 12.96% |
| GE Stock Forecast | General Electric | Outperform |
9
|
$81.96 | $86.47 | 6.15% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$245.84 | $268.00 | 11.86% |
Bio-Rad Laboratories Free Cash Flow Forecast for 2023 - 2025 - 2030
Bio-Rad Laboratories's Free Cash Flow has increased by 49.07% In the last two years, going from $359.37M to $535.72M. According to 0 prominent analysts, Bio-Rad Laboratories's Free Cash Flow will fall by 15.54% in the next year, reaching $452.45M. By 2030, professionals believe that Bio-Rad Laboratories's Free Cash Flow will decrease by 13.64%, reaching $462.64M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
16
|
$117.49 | $147.79 | 1.71% |
| SHL Stock Forecast | Siemens Healthineers | Outperform |
18
|
54.04€ | 61.61€ | 7.33% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
56.68€ | 74.54€ | 33.20% |
Bio-Rad Laboratories Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Bio-Rad Laboratories's Net Income has grown, increasing from $1.76B to $4.25B – an increase of 141.43%. For the next year, 0 analysts project Bio-Rad Laboratories's Net Income to drop by 24.83%, reaching $3.19B. By 2030, professionals believe that Bio-Rad Laboratories's Net Income will decrease by 20.48%, reaching $3.38B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$154.55 | $162.50 | 7.73% |
| LONN Stock Forecast | Lonza Group Ltd | Outperform |
16
|
CHF457.90 | CHF756.46 | 71.98% |
| ILMN Stock Forecast | Illumina Inc | Outperform |
16
|
$214.26 | $254.08 | 16.45% |
Bio-Rad Laboratories EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Bio-Rad Laboratories's EBITDA has grown, increasing from $387.06M to $687.93M – a growth of 77.73%. In the following year, 0 experts forecast Bio-Rad Laboratories's EBITDA will decrease by 23.41%, to $526.86M. In 2030, professionals predict that Bio-Rad Laboratories's EBITDA will decrease by 19.73%, to $552.18M.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 7751 Stock Forecast | Canon | Hold |
18
|
¥2.86k | ¥0.00 | 16.95% |
| HOLX Stock Forecast | Hologic Inc | Outperform |
8
|
$84.68 | $79.86 | -2.57% |
| SGSN Stock Forecast | SGS | Hold |
18
|
CHF2.25k | CHF2.84k | 27.06% |
Bio-Rad Laboratories EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Bio-Rad Laboratories's EBIT has grown by 119.14%, from $252.86M to $554.13M. According to 0 major analysts, Bio-Rad Laboratories's EBIT will fall by 30.20% in the next year, reaching $386.78M. Professionals believe that By 2030, Bio-Rad Laboratories's EBIT will fall to $419.02M– a 24.38% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| DGX Stock Forecast | Quest Diagnostics | Hold |
10
|
$142.81 | $147.77 | 1.18% |
| PKI Stock Forecast | PerkinElmer | Outperform |
16
|
$138.56 | $159.83 | 17.28% |
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
66.16€ | 0.00€ | 58.71% |
Bio-Rad Laboratories EPS Price Prediction Forecast for 2023 - 2025 - 2030
Bio-Rad Laboratories's EPS has grown in the last two years, jumping from $7.06 to $15.66 – an increase of 121.81%. The next year, 0 experts forecast that Bio-Rad Laboratories's EPS will decrease by 32.84%, reaching $10.52. In 2030, professionals predict that Bio-Rad Laboratories's EPS will decrease by 26.15%, reaching $11.57.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TECH Stock Forecast | Bio-Techne | Buy |
16
|
$79.16 | $485.91 | 31.06% |
| BVI Stock Forecast | Bureau Veritas | Outperform |
18
|
25.46€ | 27.85€ | 9.98% |
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
96.70€ | 105.55€ | 11.17% |